Tirzepatide
Mounjaro · Zepbound
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Half-Life
~5 days
MW
4813.5 Da
Amino Acids
N/A
Evidence
High Evidence
Regulatory Status
FDA-approved (Mounjaro: T2D, Zepbound: obesity). Major commercial success.
In Plain English
A "dual agonist" that activates two gut hormones simultaneously — GLP-1 and GIP. More potent for weight loss than GLP-1 alone because GIP adds an entirely separate appetite suppression pathway. The active compound in Mounjaro and Zepbound.
Overview
Tirzepatide is the first dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It combines both incretin pathways for superior glycemic control and weight loss. Clinical trials showed 20-22% mean body weight reduction, surpassing semaglutide.
Common Formats
- Pre-filled injectable pen (weekly)
- Compounded versions
Storage Notes
Refrigerate 2-8°C. Room temperature up to 21 days after first use.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Tirzepatide.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.